Ingenol Compounds for HIV Latency Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV, such as HAART, fail to completely eliminate the virus due to latent HIV reservoirs in resting CD4+ T cells, as existing activators are either ineffective or have significant toxic side effects, and there is a lack of new anti-AIDS drugs with independent intellectual property rights in China.
Innovation Solution
The use of ingenol compounds and their derivatives, which interfere with HIV latency by inducing proviral expression and activating latent viruses, potentially combined with antiretroviral drugs to accelerate the removal of latent virus reservoirs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing activators are used to induce proviral expression of HIV latent-infected cells, then the activation of latent viruses is improved, but toxic side effects increase significantly
Solution Approach 1:
The patent modifies the chemical structure of ingenol by changing parameters such as substituting hydroxyl groups with different protecting groups (acetate, benzoate, pivalate), altering the carbon chain length and saturation at specific positions (C13, C14, C15), and varying the ester groups at positions 3, 13, and 20. These parameter changes result in derivatives with improved activation efficacy and reduced toxicity compared to natural ingenol.
Solution Approach 2:
The patent creates composite chemical structures by combining the ingenol core skeleton with various substituent groups including butanoyl, benzoate, pivalate, and long-chain fatty acid esters. These composite structures achieve synergistic effects where the ingenol core provides the biological activity while the substituents modulate the pharmacological properties to reduce toxicity.
2Quantity of substance
If HAART treatment is applied to control HIV replication, then viral load is reduced to undetectable levels, but latent virus reservoirs in resting CD4+ T cells persist
Solution Approach 1:
The patent applies ingenol compounds before or during HAART treatment to induce proviral expression in latently infected cells. By activating the latent viruses in advance, the subsequent HAART treatment can more effectively target and eliminate the virus reservoirs, achieving preliminary action against the hidden virus population that HAART alone cannot reach.
Solution Approach 2:
The ingenol compounds act as intermediary substances that bridge the gap between HAART treatment and latent virus elimination. They mediate the activation of latent viruses, making them susceptible to immune system attack and HAART, thereby enabling the combination therapy to achieve complete virus eradication where HAART alone fails.
3Adaptability or versatility
If new anti-AIDS drugs with independent intellectual property rights are developed, then treatment options are improved, but research and development time and resources increase
Solution Approach 1:
The patent segments the development process by focusing on modifying a known active compound (ingenol) through systematic structural variations rather than de novo drug discovery. This segmentation into manageable structural modifications (changing specific substituents, protecting groups, and chain lengths) accelerates development while ensuring intellectual property protection through novel derivatives.
Data Source
AI summary
Provided in the present invention are ingenol compounds and a use thereof in preparing an anti-HIV latency drug. In particular, provided in the present invention is a use of ingenol compounds and pharmaceutically acceptable salts thereof for preparing a drug for: (a) intervening with HIV viral latency; (b) activating an HIV virus that has been integrated into mammalian genomes; and/or (c) inducing the expression of the dormant HIV provirus in infected cells. The compounds of the present invention may also be used in combination with antiretroviral drugs to accelerate the removal of latent viral reservoirs.